OrthoLogic to start phase III fracture repair trial:
This article was originally published in Clinica
Executive Summary
The US FDA has given OrthoLogic the go-ahead to begin a phase III clinical trial of its injectable synthetic peptide product, Chrysalin, for accelerating fracture repair. The trial is scheduled to begin enrolling around 500 patients from 25 to 30 medical centres this autumn. The enrolment process is expected to take approximately 24 months, with a six-month follow-up period. OrthoLogic, of Tempe, Arizona, has obtained the worldwide rights to use Chrysalin for all orthopaedic indications through a series of agreements with Galveston, Texas-based Chrysalis BioTechnology. Chrysalin's application for spinal fusion and articular cartilage defect repair is also being explored.
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.